Profund Advisors LLC Buys 605 Shares of IDEXX Laboratories, Inc. $IDXX

Profund Advisors LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.4% in the second quarter, HoldingsChannel.com reports. The fund owned 7,008 shares of the company’s stock after acquiring an additional 605 shares during the period. Profund Advisors LLC’s holdings in IDEXX Laboratories were worth $3,759,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Allworth Financial LP grew its position in shares of IDEXX Laboratories by 3.2% in the 1st quarter. Allworth Financial LP now owns 1,555 shares of the company’s stock valued at $686,000 after purchasing an additional 48 shares during the period. Alps Advisors Inc. bought a new stake in shares of IDEXX Laboratories in the first quarter valued at about $357,000. Cerity Partners LLC lifted its holdings in shares of IDEXX Laboratories by 63.5% in the first quarter. Cerity Partners LLC now owns 18,630 shares of the company’s stock valued at $7,824,000 after purchasing an additional 7,235 shares in the last quarter. Diversify Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the first quarter worth about $518,000. Finally, Ballentine Partners LLC grew its holdings in shares of IDEXX Laboratories by 20.7% during the first quarter. Ballentine Partners LLC now owns 1,478 shares of the company’s stock worth $621,000 after buying an additional 253 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on IDXX shares. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. BTIG Research upped their price target on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $730.50.

IDEXX Laboratories Trading Down 0.7%

Shares of IDXX stock opened at $708.45 on Monday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $735.00. The stock’s fifty day moving average price is $645.28 and its two-hundred day moving average price is $580.40. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a market cap of $56.57 billion, a PE ratio of 58.99, a P/E/G ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the firm posted $2.80 earnings per share. IDEXX Laboratories’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Michael G. Erickson sold 406 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the sale, the executive vice president directly owned 11,287 shares in the company, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.